We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold Teladoc Health (TDOC) Stock Now
Read MoreHide Full Article
Teladoc Health, Inc. (TDOC - Free Report) is currently aided by growing membership, an advanced telehealth platform, an array of buyouts and tie-ups coupled with strong cash reserves.
Zacks Rank & Price Rally
Teladoc Health currently carries a Zacks Rank #3 (Hold).
The stock has gained 8.9% in the past six months against the industry’s 0.1% decline.
Image Source: Zacks Investment Research
Favorable Style Score
TDOC carries an impressive VGM Score of A. Value Score helps find stocks that are undervalued. Here V stands for Value, G for Growth and M for Momentum, and the score is a weighted combination of all three factors.
Impressive Earnings Surprise History
Teladoc Health boasts an impressive surprise record. Its earnings outpaced estimates in each of the trailing four quarters, the average being 22.78%.
Business Tailwinds
Revenues of the virtual care provider benefit on the back of growing membership and higher patient visits. An aging U.S. population, belonging to a vulnerable community, plus increased confidence to opt for outpatient visits following the receding impacts of the COVID pandemic are likely to sustain the solid demand for the TDOC’s services in the days ahead.
For 2023, management anticipates revenues between $2,550 million and $2,675 million, the mid-point of which suggests 8.5% growth from the 2022 figure.
Teladoc Health has a robust telehealth platform in place for addressing the strong demand for virtual care which has been in huge demand since 2020 with no signs of slowing down. The platform was built through advanced technologies, partnerships with well-established healthcare providers and substantial investments. It also continues to launch whole-person virtual care solutions integrated with lucrative features from time to time.
In fact, the strength of this platform provides an opportunity for Teladoc Health to establish a solid foothold across the global virtual care market. Leveraging the platform, clinicians of TDOC’s clients were able to complete around 4.2 million visits for patients across the globe last year.
TDOC has also resorted to a series of buyouts and collaborations, which have boosted healthcare capabilities and diversified its treatment networks. In order to pursue such growth-related initiatives, a strong financial position is a dire need and that has exactly been the case with Teladoc Health. It boasts a growing cash balance and adequate cash-generating abilities. As of Dec 31, 2022, cash and cash equivalents increased 2.8% from the 2021-end level.
Masimo’s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average beat being 9.02%. The Zacks Consensus Estimate for MASI’s 2023 earnings suggests an improvement of 3.5%, while the same for revenues indicates growth of 19.5% from the respective year-ago figures.
The Zacks Consensus Estimate for MASI’s 2023 earnings has moved 1.9% north in the past 30 days. Shares of Masimo have gained 45.7% in the past six months.
LivaNova’s earnings surpassed estimates in three of the last four quarters and missed the mark once, the average being 2.62%. The Zacks Consensus Estimate for LIVN’s 2023 earnings indicates a 8% rise, while the same for revenues suggests an improvement of 5.1% from the respective prior-year figures.
The consensus mark for LIVN’s 2023 earnings has moved 4.9% north in the past 60 days. Shares of LivaNova have declined 1.3% in the past six months.
Stevanato Group’s earnings outpaced estimates in each of the trailing four quarters, the average being 10.97%. The Zacks Consensus Estimate for STVN’s 2023 earnings indicates a 8.5% rise, while the same for revenues suggests an improvement of 12.5% from the respective prior-year estimates.
The consensus mark for STVN’s 2023 earnings has moved up 14.3% in the past 60 days. Shares of Stevanato Group have gained 49.8% in the past six months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Here's Why You Should Hold Teladoc Health (TDOC) Stock Now
Teladoc Health, Inc. (TDOC - Free Report) is currently aided by growing membership, an advanced telehealth platform, an array of buyouts and tie-ups coupled with strong cash reserves.
Zacks Rank & Price Rally
Teladoc Health currently carries a Zacks Rank #3 (Hold).
The stock has gained 8.9% in the past six months against the industry’s 0.1% decline.
Image Source: Zacks Investment Research
Favorable Style Score
TDOC carries an impressive VGM Score of A. Value Score helps find stocks that are undervalued. Here V stands for Value, G for Growth and M for Momentum, and the score is a weighted combination of all three factors.
Impressive Earnings Surprise History
Teladoc Health boasts an impressive surprise record. Its earnings outpaced estimates in each of the trailing four quarters, the average being 22.78%.
Business Tailwinds
Revenues of the virtual care provider benefit on the back of growing membership and higher patient visits. An aging U.S. population, belonging to a vulnerable community, plus increased confidence to opt for outpatient visits following the receding impacts of the COVID pandemic are likely to sustain the solid demand for the TDOC’s services in the days ahead.
For 2023, management anticipates revenues between $2,550 million and $2,675 million, the mid-point of which suggests 8.5% growth from the 2022 figure.
Teladoc Health has a robust telehealth platform in place for addressing the strong demand for virtual care which has been in huge demand since 2020 with no signs of slowing down. The platform was built through advanced technologies, partnerships with well-established healthcare providers and substantial investments. It also continues to launch whole-person virtual care solutions integrated with lucrative features from time to time.
In fact, the strength of this platform provides an opportunity for Teladoc Health to establish a solid foothold across the global virtual care market. Leveraging the platform, clinicians of TDOC’s clients were able to complete around 4.2 million visits for patients across the globe last year.
TDOC has also resorted to a series of buyouts and collaborations, which have boosted healthcare capabilities and diversified its treatment networks. In order to pursue such growth-related initiatives, a strong financial position is a dire need and that has exactly been the case with Teladoc Health. It boasts a growing cash balance and adequate cash-generating abilities. As of Dec 31, 2022, cash and cash equivalents increased 2.8% from the 2021-end level.
Stocks to Consider
Some better-ranked stocks in the Medical space are Masimo Corporation (MASI - Free Report) , LivaNova PLC (LIVN - Free Report) and Stevanato Group S.p.A. (STVN - Free Report) . While Masimo currently sports a Zacks Rank #1 (Strong Buy), LivaNova and Stevanato Group carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average beat being 9.02%. The Zacks Consensus Estimate for MASI’s 2023 earnings suggests an improvement of 3.5%, while the same for revenues indicates growth of 19.5% from the respective year-ago figures.
The Zacks Consensus Estimate for MASI’s 2023 earnings has moved 1.9% north in the past 30 days. Shares of Masimo have gained 45.7% in the past six months.
LivaNova’s earnings surpassed estimates in three of the last four quarters and missed the mark once, the average being 2.62%. The Zacks Consensus Estimate for LIVN’s 2023 earnings indicates a 8% rise, while the same for revenues suggests an improvement of 5.1% from the respective prior-year figures.
The consensus mark for LIVN’s 2023 earnings has moved 4.9% north in the past 60 days. Shares of LivaNova have declined 1.3% in the past six months.
Stevanato Group’s earnings outpaced estimates in each of the trailing four quarters, the average being 10.97%. The Zacks Consensus Estimate for STVN’s 2023 earnings indicates a 8.5% rise, while the same for revenues suggests an improvement of 12.5% from the respective prior-year estimates.
The consensus mark for STVN’s 2023 earnings has moved up 14.3% in the past 60 days. Shares of Stevanato Group have gained 49.8% in the past six months.